Anand Mehra, M.D.
General Partner, Sofinnova Ventures
Dr. Anand Mehra joined Sofinnova Ventures in 2007 and is focused on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Aclaris and Prothena, and he played a key role in the firm’s investments in SarCode (acquired by Shire), Preglem (acquired by Gedeon Richter) and Amarin. In addition to Spark Therapeutics, Anand is currently a director of Aerie and Marinus Pharmaceuticals and was on the board of Nextwave Pharmaceuticals until its acquisition by Pfizer.
Prior to joining Sofinnova, Anand worked in JP Morgan’s private equity and venture capital group, where he was heavily involved in new investments, management of their public portfolio and the firm’s spin-out from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Company’s pharmaceutical practice, advising pharma and biotech on key strategic issues, and an NIH-funded fellow focused on reperfusion injury in stroke.
Anand received his M.D. from Columbia University’s College of Physicians and Surgeons and graduated Phi Beta Kappa from the University of Virginia, where he was an Echols Scholar.